Lymfactin® for the Treatment of Lymphedema
Lymfactin® in Patients
Lymfactin® aims to become the first drug for treating secondary lymphedema. It is presently being developed for the treatment of breast cancer-related lymphedema (BCRL) in patients who undergo lymph node transplantation surgery with or without breast reconstruction. Lymfactin® has been studied in Phase 1 and Phase 2 clinical studies. Both studies are currently in a long-term follow-up and the patient recruitment has been completed. More information about the Phase 2 clinical study can be found at www.lymfactin.fi/en.
We are frequently contacted by patients and physicians enquiring about the possibility to use Lymfactin® for the treatment of other lymphedemas. While we believe in the potential of Lymfactin® beyond BCRL, for ethical and regulatory reasons we are currently focused on BCRL. Any concrete plans for expansion in other lymphedemas would be announced when appropriate by the company.
Secondary lymphedema is caused by injuries of the lymphatic system, which can manifest as a result of cancer treatments such as surgery and radiotherapy. The injuries of the lymphatic system may result in the accumulation of lymph in tissue in areas such as the limbs. This leads to a chronic, progressive swelling.
Secondary lymphedema is a painful, deforming disease that often has a significant impact on the quality of life of the patients. Symptoms of secondary lymphedema include progressive swelling of the affected limb, pain, decreased mobility, and increased forming of connective tissue. Many patients also suffer from repeated infections of the affected tissue.
Lymfactin® is a gene therapy that promotes the formation of new lymphatic vessels in the damaged area, to reconstitute a functional lymphatic system. This is accomplished with the natural human growth factor Vascular Endothelial Growth Factor C (VEGF-C), which is necessary for the creation of new lymphatic vessels.
Lymfactin® is injected locally at the damaged site of the lymphatic system. This is expected to stimulate the formation of new lymphatic vessels. This may eventually normalize the lymphatic flow and thereby stop the accumulation of the lymph in tissue in patients. For more detailed information on the mechanism of action please see here.
Introductory video on Lymfactin®